Jakubowitz Law Reminds Revance Shareholders of a Lead Plaintiff Deadline of February 8, 2022


NEW YORK, Feb. 4, 2022 /PRNewswire/ — Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC).

To receive updates on the lawsuit, fill out the form:


The lawsuit seeks to recover losses for shareholders who purchased Revance between November 25, 2019 and October 11, 2021.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until February 8, 2022 to petition the court. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

According to a filed complaint, Revance Therapeutics, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) quality control deficiencies existed at the Company’s manufacturing facility for DaxibotulinumtoxinA for Injection (“DAXI”); (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration (“FDA”) would approve the DAXI Biologics License Application (“BLA”) in its current form; (iii) accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE Jakubowitz Law

Source link